Larkspur Health Acquisition Corp. Stock: price and directors' dealings · United States · SEC (Form 4)

About Larkspur Health Acquisition Corp.

Larkspur Health Acquisition Corp. was a Delaware-incorporated SPAC created on March 17, 2021 for the purpose of completing a merger, stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination. Before the transaction, Larkspur itself had no operating business; in SEC filings it described itself as a blank-check company. Its principal executive offices were in Bridgewater, New Jersey, United States. The company’s core investment relevance comes from the business combination announced with ZyVersa Therapeutics, a Florida-based biopharmaceutical company. In other words, Larkspur should be viewed primarily as the listing vehicle that brought a biotech business to the public market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1859007/000121390022047444/fs42022_larkspurhealth.htm?utm_source=openai)) From an operating perspective, the post-combination story is centered on ZyVersa’s clinical-stage pipeline in renal and inflammatory disease rather than on any legacy SPAC activity. ZyVersa describes itself as a specialty biopharmaceutical company leveraging proprietary technologies to develop first-in-class therapies for unmet medical needs. Its lead renal program is VAR 200, a cholesterol efflux mediator designed to reduce harmful lipid accumulation in the kidney’s filtration system and potentially slow kidney damage. The lead indication is focal segmental glomerulosclerosis (FSGS), with additional development potential in Alport syndrome and diabetic kidney disease. The company also advances IC 100, an inflammasome ASC inhibitor aimed at inflammatory pathways implicated in multiple central nervous system and peripheral inflammatory disorders. ([zyversa.com](https://www.zyversa.com/about?utm_source=openai)) In competitive terms, the company operates in a highly specialized biotech niche where valuation is driven by clinical proof-of-concept, regulatory progress, intellectual property, and financing capacity. It does not compete as a commercial-stage pharma platform; instead, it competes for scientific validation and capital against other development-stage companies targeting rare or underserved kidney and inflammatory diseases. That makes the equity profile inherently binary and milestone-driven. ZyVersa’s recent disclosures highlighted a meaningful near-term catalyst: in June 2025, the first clinical site for a Phase 2a study of VAR 200 in diabetic kidney disease was activated, with patient screening underway and interim results expected around Q4 2025. For investors following Form 4 insider activity, this kind of milestone matters because insider buying or selling can be interpreted against a backdrop of binary clinical risk and cash runway sensitivity. ([investors.zyversa.com](https://investors.zyversa.com/news-releases/news-release-details/zyversa-therapeutics-reports-second-quarter-2025-financial/?utm_source=openai)) Overall, Larkspur Health Acquisition Corp. is best understood as a former SPAC now tied to ZyVersa Therapeutics’ biotech pipeline, listed in the United States on the NASDAQ context referenced in the merger materials. The investment case is driven by clinical development progress, not by a mature operating history, and it remains a high-risk, high-optionalty healthcare name. ([nasdaq.com](https://www.nasdaq.com/press-release/sec-declares-form-s-4-registration-statement-effective-for-proposed-business?utm_source=openai))